Complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) is characterized by early-onset gastrointestinal symptoms, edema, malnutrition, hypoalbuminemia, and hypogammaglobulinemia. It has been reported that mutations in CD55 cause this syndrome. CD55 encodes the decay-accelerating factor (DAF), a widely expressed glycosylphosphatidylinositol-linked membrane protein. DAF regulates complement activation by inhibiting C3 and C5 cleavage and activation, thus protecting cells against complement-induced self-injury.
